Clinical Trials Logo

HHT clinical trials

View clinical trials related to HHT.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06266624 Active, not recruiting - HHT Clinical Trials

Tourniquet-Test in HHT

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.

NCT ID: NCT05550376 Active, not recruiting - Clinical trials for Hereditary Hemorrhagic Telangiectasia

Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia

Generate-HHT
Start date: April 30, 2021
Phase:
Study type: Observational [Patient Registry]

The present project aims to study the inflammatory and endothelial responses involved in the differences in clinical events related to both genotypes (ENG vs. ACVRL1) in HHT. Accordingly, a cross-sectional study is proposed to evaluate the differences in circulating inflammatory and endothelial biomarkers, including interleukines, adhesion molecules, chemokines and immune regulatory molecules between both HHT groups.

NCT ID: NCT04150822 Active, not recruiting - Clinical trials for Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry

HHT
Start date: November 1, 2018
Phase:
Study type: Observational [Patient Registry]

The goal of this study is to better understand HHT, the symptoms and complications it causes ("outcomes") and how the disease impacts people's lives. The investigators are aiming to recruit and gather information together in the Registry from 1,000 HHT patients from four HHT Centres of Excellence in North America. The Investigators will collect long-term information about the people in the Registry, allowing the investigators to understand how the disease changes over time, and what factors can influence those changes. Ultimately, this should help improve treatments for the disease.